448 results about "Glaucoma present" patented technology

The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and / or a symptom associated therewith, wherein the composition comprises tafluprost and a semifluorinated alkane.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device, tool, or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Some systems described here may be configured to cut or tear the trabecular meshwork with the body of an elongate member located within Schlemm's canal. Other tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

The invention discloses a multi-modal data glaucoma classification method and system, a terminal and a medium, and the method comprises the steps: obtaining a color fundus image and an OCT image in different image modes, and carrying out the advanced feature extraction of the color fundus image and the OCT image based on a first feature extraction module and a second feature extraction module, the mode specificity characteristics of the two modes are obtained; fusing the mode specific features of the two modes based on a shallow feature fusion module to obtain shallow fusion features; inputting the mode specific features of the two modes and the shallow fusion features into a deep feature fusion module for fusion to obtain final fusion features; and based on a multi-layer perceptron classifier, performing classification prediction on the final fusion feature to obtain a classification result, the classification result including no glaucoma, early glaucoma or mid-late glaucoma. According to the method, through two-stage feature extraction, two-stage feature fusion and the classifier, accurate glaucoma classification can be obtained.

Adjustable flow glaucoma shunts are disclosed herein. In one embodiment, for example, an adjustable flow shunt can include an outflow drainage tube having a proximal inflow region and a distal outflow region. The proximal inflow region can include aperture(s) defining a fluid inlet area positioned to allow fluid to flow therethrough. The shunt further comprises an inflow control assembly at the proximal inflow region. The inflow control assembly can include a control element configured to slidably engage the proximal inflow region and a spring element. The spring element is configured to be activated by non-invasive energy and, upon activation, slidably move the control element along the proximal inflow region such that (a) the one or more apertures are accessible and have a first fluid flow cross-section or (b) the one or more apertures are at least partially covered by the control element and have a second, different fluid-flow cross-section.

Systems and devices for facilitating the flow of fluid between a first body region and a second body region are disclosed herein. The devices generally include a drainage and / or shunting element having a lumen extending therethrough for draining or otherwise shunting fluid between the first and second body regions. Further, devices configured in accordance with the present technology may be selectively adjustable to control the amount of fluid flowing between the first and second body regions. In some embodiments, for example, the devices comprise an actuation assembly that drives movement of a flow control element to modulate flow resistance through the lumen, thereby increasing or decreasing the relative drainage rate of fluid between the first body region and the second body region.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

The invention discloses a glaucoma distinguishing detection method and system based on multi-modal fusion. The method relates to the technical field of glaucoma distinguishing detection, and comprises the following steps: collecting glaucoma distinguishing detection data; analyzing glaucoma distinguishing detection data; and comprehensively analyzing, optimizing and adjusting the glaucoma distinguishing detection data quality accuracy. The glaucoma distinguishing detection data is collected and processed, the glaucoma distinguishing detection data is analyzed, the glaucoma distinguishing detection data integrity evaluation index and the glaucoma distinguishing detection data image quality evaluation index are obtained, and the glaucoma distinguishing detection data quality accuracy method is comprehensively analyzed, optimized and adjusted. The accuracy of the glaucoma distinguishing and detecting method and system based on multi-modal fusion is improved, and the problem that the accuracy of the glaucoma distinguishing and detecting method and system based on multi-modal fusion is insufficient in the prior art is solved.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

A glaucoma aqueous humor drainage tube implantation and injection device, which relates to the field of ophthalmology. The glaucoma aqueous humor drainage tube implantation and injection device comprises a protective housing (1), wherein an adjustable lower housing (8) is slidably connected to an inner wall of the protective housing (1), a fixing post (3) is fixedly connected to a surface of the protective housing (1), a left opening and clamping plate (4) and a right opening and clamping plate (5) are each rotationally connected to a surface of the fixing post (3), contact plates (6) are fixedly connected to both the bottom ends of the left opening and clamping plate (4) and the right opening and clamping plate (5), adhesive stickers (7) are fixedly connected to both the lower surfaces of the pair of contact plates (6), an adjustable rotating cylinder (2) is rotationally connected to the inner wall of the protective housing (1), and an adjustable pressure-reducing mechanism (9) is in threaded connection with an inner wall of the adjustable rotating cylinder (2). The adhesive stickers (7) are provided to adhere to the skin of a human body to provide support, so as to prevent eyelids of a patient from resetting due to fatigue during surgery; by means of providing the left opening and clamping plate (4) and the right opening and clamping plate (5), balanced support is maintained; by providing the protective housing (1), the movement of the adjustable lower housing (8) is guided and positioned; the adjustable pressure-reducing mechanism (9) is provided such that the eyelids of the patient are supported and tensioned during surgery and remain stable; and the functions of needling and of aqueous humor flow guiding are integrated, so as to avoid frequent replacement of a device during surgery.

Systems, devices, and methods for treating a glaucomatous eye are provided. An amount of pulsed laser energy is delivered to the pars plana of the eye by a hand-holdable device which comprises a hand-holdable elongate member and a contact member disposed on an end of the elongate member. A contact surface of the contact member is placed in direct contact with the eye so that a reference edge of the contact member aligns with the limbus and a treatment axis defined by the elongate member is angularly offset from the optical axis of the eye. The amount of pulsed laser energy delivered is insufficient to effect therapeutic photocoagulation but is sufficient to increase uveoscleral outflow so as to maintain a reduction from pre-laser treatment intraocular pressure. Amounts of pulsed laser energy will be transmitted to a circumferential series of tissue regions of the eye.

A wireless passive resonance sensor and contact lens for intraocular pressure monitoring comprises a contact lens body which is used for packaging a sensor assembly and serves as a substrate of the sensor. The first spiral inductor is arranged in the contact lens body; the middle elastic dielectric layer covers the first spiral inductor and is used for forming a deformable dielectric medium; the second spiral inductor is arranged on the middle-layer elastic dielectric layer, is opposite to the first spiral inductor and forms an inductor assembly with the first spiral inductor; wherein the first spiral inductor, the middle elastic dielectric layer and the second spiral inductor jointly form a capacitor and equivalently form a serial L-C-L resonant circuit, and the change of intraocular pressure is responded through the change of resonant frequency of the resonant circuit, so that passive wireless monitoring is realized. The design optimizes the preparation process, reduces the cost, improves the signal stability, is suitable for 24-hour continuous monitoring, and provides a powerful tool for early diagnosis and intervention of glaucoma.

The invention relates to the technical field of computer vision, in particular to a multi-modal intelligent glaucoma recognition method and system based on transfer learning, and the method comprises the following steps: collecting fundus images of a glaucoma patient in multiple stages based on medical image data, analyzing the texture and shape changes in the images, and obtaining a multi-modal image; and simulating changes of the pathological features in a plurality of development stages, and generating a dynamic pathological feature sequence. According to the method, retina changes of a glaucoma patient in multiple disease development stages are simulated, visual feature information of pathological features in multiple development stages is captured, visual features of fundus images of the patient are extracted and compared, the disease development stages of the patient are evaluated, and the feature recognition process is optimized in combination with transfer learning. The method improves the generalization ability of the model and the diagnosis accuracy, achieves the accurate evaluation of the visual impairment through combining the measurement and prediction of the intraocular pressure data, and helps medical personnel to judge the retina state of a glaucoma patient.

According to the glaucoma multi-mode auxiliary diagnosis device and the electronic equipment, firstly, first feature extraction and second feature extraction are carried out on an eye fundus image and an OCT image respectively, then semantic spaces of an eye fundus image mode and an OCT image mode are aligned by utilizing comparison loss, and the first feature and the second feature are fused by utilizing a cross attention mechanism, so that an eye fundus image is obtained. According to the method, the two modal data are subjected to fusion to obtain fusion features, then the fusion features are subjected to feature extraction to obtain third features, and glaucoma classification judgment is performed based on the third features, so that global modeling of the two modal data can be realized, effective features are extracted to perform glaucoma classification judgment, and the accuracy and timeliness of diagnosis are ensured.

The invention provides an eye drop composition as well as a preparation method and application thereof, and belongs to the technical field of ophthalmic preparations. The eye drop composition adopted by the invention is prepared from the following components: brimonidine tartrate, hyaluronic acid, collagen, trehalose and injection water. By compounding the components, the eye drops which can realize slow release of brimonidine tartrate and prolong the antihypertensive action time and have the characteristics of relieving blink discomfort, long-acting moisturizing, anti-inflammatory soothing, mildness, corrosion prevention and the like are prepared; the eye drops are beneficial to people suffering from glaucoma, intraocular hypertension, xerophthalmia, postoperative inflammation or allergy and preservative sensitivity or preservative allergy, the life quality is improved, and diseases are relieved.

Described herein are compositions and methods for expressing therapeutic agents. Compositions comprise an engineered polypeptide comprising a natriuretic peptide linked to an antibody or fragment thereof. Also disclosed are AAV vectors encoding the engineered polypeptides, and therapeutic uses thereof for the treatment of diseases such as glaucoma.

The invention belongs to the technical field of medicines, and discloses an application of a Necrosulfenamide (NSA) compound in preparation of a medicine for resisting glaucoma trabecular network fibrosis. The NSA can inhibit abnormal activation of necroptosis-related pathways and significantly down-regulate fibrosis key factors, so that the structure and function of trabecular meshwork tissues are improved, and the aqueous humor outflow capacity is recovered. It is found for the first time that NSA not only has a stable and lasting intraocular pressure lowering effect, but also can reduce retinal ganglion cell damage in an intraocular hypertension state, and has definite treatment and protection effects on non-acute glaucoma and intraocular hypertension. The regulation effect of NSA on trabecular meshwork fibrosis is not disclosed in the prior art, the research blank in the field is filled, and a new pharmacological target and a clinical application strategy are provided for prevention and treatment of glaucoma and related intraocular hypertension diseases.

Microemulsions are disclosed herein that include a discontinuous internal phase comprising an aqueous solution encompassed within an internal emulsifier, a continuous oil phase encompassing the internal phase; and an external emulsifier encompassing the oil phase. Also disclosed are methods for the use of such microemulsions as drug delivery devices, and methods for treating glaucoma and reducing intraocular pressure.

The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

Glaucoma shunts comprising an elongate body with an outer surface and an inner surface, the elongate body comprising an inner wall that defines a lumen spanning a length of the elongate body are disclosed herein. Also disclosed are methods of decreasing intraocular pressure in an eye, the method comprising inserting at least a portion of a glaucoma shunt into an anterior chamber of the eye, and draining aqueous humour from the anterior chamber through the lumen.

1. Name of the design product: Graphical user interface for glaucoma gait feature setting of an electronic device. 2. Use of the design product: An electronic device. 3. Design key points of the design product: Lies in the graphical user interface. 4. Picture or photo that best shows the design key points: The front view of Design 1. 5. The electronic device is of a conventional design, and the rear view, left view, right view, top view, and bottom view are omitted. 6. Design 1 is designated as the basic design. 7. Use of the graphical user interface: The front view of Design 1 is the operation interface for logging in to the glaucoma gait feature construction system. The user clicks "Glaucoma-1" in the front view of Design 1 to enter Figure 1 of the interface state change of Design 1. The user clicks "01-1" in Figure 1 of the interface state change of Design 1 to enter Figure 2 of the interface state change of Design 1. The user clicks "celling light" in Figure 2 of the interface state change of Design 1 to enter Figure 3 of the interface state change; The front view of Design 2 is the operation interface for logging in to the glaucoma gait feature construction system. The user clicks "Glaucoma-1" in the front view of Design 2 to enter Figure 1 of the interface state change of Design 2. The user clicks "01-1" in Figure 1 of the interface state change of Design 2 to enter Figure 2 of the interface state change of Design 2. The user slides the left menu in Figure 2 of the interface state change of Design 2 and then clicks "Targets" to enter Figure 3 of the interface state change of Design 2; The user clicks "01Chest" in Figure 3 of the interface state change of Design 2 to enter Figure 4 of the interface state change of Design 2; The front view of Design 3 is the operation interface for logging in to the glaucoma gait feature construction system. The user clicks "Glaucoma-1" in the front view of Design 3 to enter Figure 1 of the interface state change of Design 3. The user clicks "01-1" in Figure 1 of the interface state change of Design 3 to enter Figure 2 of the interface state change of Design 3. The user slides the left menu in Figure 2 of the interface state change of Design 3 and then clicks "shengao" to enter Figure 3 of the interface state change of Design 3; The front view of Design 4 is the operation interface for logging in to the glaucoma gait feature construction system. The user clicks "Glaucoma-1" in the front view of Design 4 to enter Figure 1 of the interface state change of Design 4. The user clicks "01-1" in Figure 1 of the interface state change of Design 4 to enter Figure 2 of the interface state change of Design 4. The user slides the left menu in Figure 2 of the interface state change of Design 4 and then clicks "f666d6de-10c9-4c0f-8b" to enter Figure 3 of the interface state change of Design 2. 8. Other situations that need to be explained: Other explanations: The gray part in the picture is variable content. It can display different contents according to the user's personalized operations.

Apparatus and methods are provided for treating diseases that produce elevated intraocular pressures, such as glaucoma, wherein the device includes a housing shell defining a cavity between a first end and a second end of the housing shell, and an elastic membrane disposed within the cavity to divide the cavity into a fluidic channel that permits a flow of fluid from the first end to the second end and a sealed cavity. The elastic membrane deforms to change the volume of the sealed cavity responsive to pressure fluctuations between the first and second ends, thereby varying the fluidic resistance of the flow of fluid through the fluidic channel.

Disclosed are a series of isoquinolone derivatives as ROCK protein kinase inhibitors and uses thereof in preparing medicaments for ROCK protein kinase inhibitor-related glaucoma or ocular hypertension diseases. Specially, disclosed are a compound of formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

Described here are systems and methods for accessing Schlemm's canal and for delivering an ocular device, tool, or fluid composition therein. The ocular devices may maintain the patency of Schlemm's canal without substantially interfering with transmural fluid flow across the canal. The fluid composition may be a viscoelastic fluid that is delivered into the canal to facilitate drainage of aqueous humor by disrupting the canal and surrounding trabeculocanalicular tissues. Some systems described here may be configured to cut or tear the trabecular meshwork with the body of an elongate member located within Schlemm's canal. Other tools for disrupting these tissues and minimally invasive methods for treating medical conditions associated with elevated intraocular pressure, including glaucoma, are also described.

Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.

The present disclosure relates to the treatment and / or prevention of glaucoma and other diseases affecting the optic nerve and retinal ganglion cells. In particular, the present disclosure provides novel therapeutic antibodies, and related compositions and methods, that target angiopoietin-related protein 7 (ANGPTL7) to reduce intraocular pressure (IOP) in order to prevent optic nerve damage and restore vision.

The invention discloses an application of a sophora flavescens ethyl acetate part and an active component thereof in resisting glaucoma trabecular meshwork fibrosis, relates to the field of biological medicines, and innovatively discovers the effect of the sophora flavescens ethyl acetate part and the active component thereof in resisting glaucoma trabecular meshwork fibrosis. The compound can be applied to preparation of drugs for resisting trabecular meshwork cell fibrosis and preventing and treating trabecular meshwork cell fibrosis related diseases such as glaucoma.

The invention discloses preparation of a light-operated adhesion anti-oxidation, anti-inflammatory and anti-fibrosis hydrogel implant and application of the light-operated adhesion anti-oxidation, anti-inflammatory and anti-fibrosis hydrogel implant in resisting glaucoma postoperative scars. The hydrogel disclosed by the invention is composed of a carboxymethyl chitosan derivative formed by modifying carboxymethyl chitosan with phenylboronic acid and o-nitrobenzyl alcohol respectively, and a polyphenol anti-inflammatory and antioxidant drug, wherein the phenylboronic acid modified carboxymethyl chitosan derivative and the polyphenol drug form a phenylboronic acid ester bond with active oxygen response; the o-nitrobenzyl alcohol modified carboxymethyl chitosan derivative is triggered by ultraviolet light and can form a dynamic covalent imine bond with an amino group on a tissue or a polymer. The hydrogel provided by the invention can enhance the adhesion to conjunctiva through light triggering at a glaucoma filtration wound part, and the viscous implant can realize an anti-fiber effect. In addition, the anti-inflammatory and anti-oxidation medicine loaded in the hydrogel can respond to wound active oxygen release, and postoperative wound oxidative stress and inflammatory response are relieved.

The invention relates to the technical field of animal disease models, and discloses a construction method of an intraocular hypertension animal model, comprising the following steps: step A, selecting an experimental animal; step B, preparing experimental instruments and reagents; c, in an anesthesia mode, deep anesthesia is carried out on the animal, and subsequent deep anesthesia is carried out; d, intraocular pressure measurement, wherein the basic intraocular pressure value is measured through anterior chamber injection. Step E, performing anterior chamber injection, and using ofloxacin antibiotic oculentum to prevent infection after an operation; and F, intraocular pressure measurement: measuring the change of the intraocular pressure value after the anterior chamber injection. According to the method, the natural pathological process of open-angle glaucoma is simulated by injecting IFN-beta into the anterior chamber, the situation that acute intraocular pressure rise is caused mainly by blocking an aqueous humor flow outlet channel like other models is avoided, and the method can better reflect the real situation of glaucoma diseases; in addition, the model avoids intraocular pressure change caused by anatomical structure change, so that the accuracy and reliability of the model are improved.

The invention discloses an application and method of SAH-CIM hydrogel in promoting survival of retinal ganglion cells in glaucoma. The hydrogel comprises a Y-type primitive composed of three DNA chains and a siRNA connector, and the nucleotide sequences of the three DNA chains are SEQ ID NO.1-SEQ ID NO.3; the method comprises the following steps: S1, constructing a Y-type primitive: mixing three DNA chains with equal molar concentration in an annealing buffer solution, performing high-temperature denaturation at 95 DEG C, and then quickly cooling to 4 DEG C to finish annealing, so as to form a stable Y-type structure with three-way cohesive ends; s2, synthesizing a siRNA (small interfering Ribonucleic Acid) connector; and S3, mixing the Y-type element and the siRNA connector according to a molar ratio of 1: 1.5 at room temperature to react for 30 minutes, and forming a three-dimensional network structure through complementary pairing driven self-assembly, thereby finally obtaining the SAH-CIM hydrogel. The SAH-CIM hydrogel provided by the invention can be used for preventing / treating ischemia-reperfusion injury and related diseases, for example, the SAH-CIM hydrogel can be used for treating glaucoma, accurate co-delivery of a neuroprotective agent and an immunomodulator can be realized, and the SAH-CIM hydrogel has the advantages of treatment accuracy and biocompatibility.